
Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.
What Happened: The Phase 4 clinical trial that’s currently underway — covering the safety, tolerability and immunogenicity of the 2025-2026 Spikevax formula — showed positive results.